The inhibition of allergen induced bronchospasm in man by oral BRL 10833.
BRL 10833, a nitroindanedione, with DSCG like activity in rat immediate type hypersensitivity, shows good absorption after oral intake in man. The ingestion of 2 and 10 mg BRL 10833/kg body weight provides protection against the immediate type allergen induced bronchoconstriction in patients with bronchial asthma. These results confirm the activity of the drug shown by inhalation.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000403:Airway Resistance; D001986:Bronchial Spasm / Q000517:prevention & control*; D002908:Chronic Disease; D004205:Cromolyn Sodium / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005541:Forced Expiratory Volume; D006801:Humans; D007189:Indans / Q000008:administration & dosage / Q000627:therapeutic use*; D007192:Indenes / Q000627:therapeutic use*; D008171:Lung Diseases / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D012130:Respiratory Hypersensitivity / Q000188:drug therapy*
D007189:Indans; D007192:Indenes; C012136:nivimedone; D004205:Cromolyn Sodium